FIB 992
Alternative Names: FIB 992 079; FIB-992Latest Information Update: 17 Jun 2026
At a glance
- Originator Fibrocor Therapeutics
- Class Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hereditary nephritis
- Discontinued Idiopathic pulmonary fibrosis; Renal fibrosis
Most Recent Events
- 17 Jun 2026 Discontinued - Preclinical for Idiopathic pulmonary fibrosis in Canada (PO) (Fibrocor Therapeutics Pipeline, June 2026)
- 17 Jun 2026 Discontinued - Preclinical for Renal fibrosis in Canada (PO) (Fibrocor Therapeutics Pipeline, June 2026)
- 17 Jun 2026 Preclinical trials in Hereditary nephritis in Canada (PO), prior to June 2026 (Fibrocor Therapeutics Pipeline, June 2026)